Protocol Ledger

NCT07533175 · Phase III · RECRUITING

AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

Interventional Phase III clinical trial protocol NCT07533175 sponsored by Novo Nordisk in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-13 Enrollment: 630 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07533175
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)630 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07533175
Protocol FieldVerified Registry Value
NCT IdentifierNCT07533175
Consolidated Lead SponsorNovo Nordisk
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment630 participants (ESTIMATED)
Registered Start Date2026-04-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07533175
Hospital Research SiteLocationSite Profile
Diablo Clinical Research IncWalnut Creek, CAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novo Nordisk across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI